|
|
|
|
|
Agalsidase beta
drug data and news
Agalsidase beta drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Agalsidase beta | ||
| Brand Names/Synonyms | Alpha-galactosidase A precursor;Melibiase;Alpha-D- galactoside galactohydrolase;Alpha-D-galactosidase A;Agalsidase alfa; Fabrazyme | ||
| Indication | For treatment of Fabry's disease (alpha-galactosidase A deficiency) | ||
| Sponsored links | Description | Recombinant human alpha-galactosidase A. The mature protein is composed of 2 subunits of 398 residues. Protein is glycosylated and produced by CHO cells | |
| Pharmacology | Used in the treatment of Fabry disease, an X-linked genetic disorder of glycosphingolipid metabolism. The disease is characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A, which leads to progressive accumulation of glycosphingolipids, predominantly GL-3, in many body tissues. Clinical manifestations of Fabry disease include renal failure, cardiomyopathy, and cerebrovascular accidents. Fabrazyme is intended to provide an exogenous source of alpha-galactosidase A and to limit the accumulation of these glycolipids in the tissues. | ||
| Mechanism Of Action | alpha-galactosidase A catalyzes the hydrolysis of globotriaosy-lceramide (GL-3) and other a-galactyl-terminated neutral glycosphingolipids, such as galabiosylceramide and blood group B substances to ceramide dihexoside and galactose. | ||
| Agalsidase beta News (When available) |
| ||
| Dosage Forms | POWDER FOR SOLUTION | ||
| Drug_Category | Enzyme replacement; enzymes (44:00.00) | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Human alpha-galactosidase A. | ||
| Chemical Formula | C2029H3080N544O587S27 | ||
| Molecular Weight | 45351.6 | ||
| Smiles String | Not Available | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.307 | ||
| Isoelectric Point | 5.17 | ||
| Biotransformation | Not Available | ||
| Half Life | 45-102 min | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Agalsidase_beta.html http://www.rxlist.com/cgi/generic3/fabrazyme.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00075 | ||
| CAS Registry Number | 104138-64-9 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA10006 | ||
| SwissProt ID | AGAL_HUMAN (P06280) | ||
| GenBank ID | X14448 | ||
| Drug ID Number [DIN] | 2248966 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |